JP2024515826A5 - - Google Patents

Info

Publication number
JP2024515826A5
JP2024515826A5 JP2023566511A JP2023566511A JP2024515826A5 JP 2024515826 A5 JP2024515826 A5 JP 2024515826A5 JP 2023566511 A JP2023566511 A JP 2023566511A JP 2023566511 A JP2023566511 A JP 2023566511A JP 2024515826 A5 JP2024515826 A5 JP 2024515826A5
Authority
JP
Japan
Prior art keywords
biodegradable
implant according
ophthalmic implant
compound
ophthalmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566511A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515826A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/027048 external-priority patent/WO2022232588A1/en
Publication of JP2024515826A publication Critical patent/JP2024515826A/ja
Publication of JP2024515826A5 publication Critical patent/JP2024515826A5/ja
Pending legal-status Critical Current

Links

JP2023566511A 2021-04-30 2022-04-29 眼疾患の処置のための薬学的組成物および硝子体内薬物送達システム Pending JP2024515826A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163182559P 2021-04-30 2021-04-30
US63/182,559 2021-04-30
US202163287737P 2021-12-09 2021-12-09
US63/287,737 2021-12-09
PCT/US2022/027048 WO2022232588A1 (en) 2021-04-30 2022-04-29 Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases

Publications (2)

Publication Number Publication Date
JP2024515826A JP2024515826A (ja) 2024-04-10
JP2024515826A5 true JP2024515826A5 (cg-RX-API-DMAC7.html) 2025-05-20

Family

ID=83848732

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566511A Pending JP2024515826A (ja) 2021-04-30 2022-04-29 眼疾患の処置のための薬学的組成物および硝子体内薬物送達システム

Country Status (10)

Country Link
US (3) US11786510B2 (cg-RX-API-DMAC7.html)
EP (1) EP4329753A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024515826A (cg-RX-API-DMAC7.html)
KR (1) KR20240004643A (cg-RX-API-DMAC7.html)
AU (1) AU2022264036A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022705A2 (cg-RX-API-DMAC7.html)
CA (1) CA3218251A1 (cg-RX-API-DMAC7.html)
IL (1) IL307997A (cg-RX-API-DMAC7.html)
MX (1) MX2023012723A (cg-RX-API-DMAC7.html)
WO (1) WO2022232588A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7664239B2 (ja) 2019-10-30 2025-04-17 パフューズ セラピューティクス, インコーポレイテッド エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
BR112023022705A2 (pt) * 2021-04-30 2024-01-16 Perfuse Therapeutics Inc Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares
CN117295520A (zh) * 2021-04-30 2023-12-26 珀弗斯治疗股份有限公司 使用内皮素受体拮抗剂治疗眼部疾病
WO2025137005A1 (en) * 2023-12-20 2025-06-26 Perfuse Therapeutics, Inc. Methods of preparing drug delivery systems for the treatment of ocular diseases
AU2024405327A1 (en) * 2023-12-20 2026-07-02 Perfuse Therapeutics, Inc. Methods of preparing drug delivery systems for the treatment of ocular diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4282793A (en) 1992-04-10 1993-11-18 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A microneedle for injection of ocular blood vessels
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US6573285B2 (en) * 2000-12-21 2003-06-03 Bristol-Myers Squibb Co. Method for preventing or treating pain by administering an endothelin antagonist
CZ20032350A3 (en) 2001-02-02 2004-03-17 Merck Patent Gmbh PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
US20030176356A1 (en) 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
CA2697057A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
PL2424530T3 (pl) 2009-04-30 2016-07-29 Univ Midwestern Sposób i kompozycja do leczenia cukrzycowej kwasicy ketonowej
US20110082151A1 (en) 2009-06-12 2011-04-07 Auspex Pharmaceuticals, Inc. Sulfonylurea modulators of endothelin receptor
AR080888A1 (es) 2010-04-12 2012-05-16 R Tech Ueno Ltd Uso de un derivado de acido graso para producir una composicion oftalmica
EP2956096A1 (en) 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
EP4046628A1 (en) 2013-10-31 2022-08-24 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
ES2813383T3 (es) 2013-12-19 2021-03-23 Tassos Georgiou Composición de ácidos grasos omega 3 para tratar enfermedades que implican daños en el sistema nervioso
ES2584534B1 (es) 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
JP2018522942A (ja) * 2015-05-29 2018-08-16 エッジ セラピューティクス インコーポレイテッド 視力障害を低減するための組成物及び方法
CN115337254A (zh) 2015-07-23 2022-11-15 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
WO2017217967A1 (en) 2016-06-13 2017-12-21 Noveome Biotherapeutics, Inc. Novel methods for delivering therapeutic agents to the eye via nasal passages
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
US11286274B2 (en) 2017-06-19 2022-03-29 Mitopower Llc Nicotinamide riboside derivatives and their uses
US10905770B2 (en) * 2017-07-17 2021-02-02 Macregen, Inc. Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases
WO2019210194A1 (en) 2018-04-26 2019-10-31 Vitrisa Therapeutics, Inc. Pegylated compositions for ocular use, and methods thereof
CA3132635A1 (en) 2019-03-05 2020-09-10 Aerie Pharmaceuticals, Inc. Pharmaceutical compositions for treating ocular diseases or disorders
KR102191180B1 (ko) * 2019-05-31 2020-12-15 삼진제약주식회사 안질환 치료용 조성물
JP7664239B2 (ja) * 2019-10-30 2025-04-17 パフューズ セラピューティクス, インコーポレイテッド エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
CA3168810A1 (en) 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
CN117295520A (zh) * 2021-04-30 2023-12-26 珀弗斯治疗股份有限公司 使用内皮素受体拮抗剂治疗眼部疾病
BR112023022705A2 (pt) * 2021-04-30 2024-01-16 Perfuse Therapeutics Inc Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares

Similar Documents

Publication Publication Date Title
US20230172842A1 (en) Sustained drug delivery implant
AU2015257651B2 (en) Compounds for treating ophthalmic diseases and disorders
RU2532333C2 (ru) Внутриглазные системы доставки лекарственного средства с замедленным высвобождением и способы лечения глазных заболеваний
CN103002884B (zh) 用前房内比马前列素植入物的眼内压降低
CN107184544A (zh) 前房内持续释放治疗药植入物
JP2022506111A5 (cg-RX-API-DMAC7.html)
JP2014014694A (ja) 血管拡張薬を含有する持続放出性眼内インプラント
JP7330510B2 (ja) 非滲出型または萎縮型の黄斑変性にて以前に失われた視力を回復させるための医薬組成物
WO2014066658A1 (en) Ketorolac-containing sustained release drug delivery systems
TW202345803A (zh) 由投予眼部藥物遞送插入物預防老年黃斑部病變之方法
CN114746079A (zh) 用于预防或治疗眼部疾病的滴眼剂组合物
JPWO2019151470A1 (ja) 眼内血管新生及び/又は眼内血管透過性亢進を伴う眼科疾患の予防又は治療のための医薬
JP6407145B2 (ja) 網脈絡膜障害の抑制剤
WO2020242264A1 (en) A composition for treating eye diseases
EP3328411A1 (en) Sustained-release drug formulations for glaucoma
HK40118703A (en) Method of treating wet age-related macular degeneration
CN118891040A (zh) 治疗湿性年龄相关性黄斑变性的方法
HK40092417A (en) Compounds for treating ophthalmic diseases and disorders
JP2009544740A5 (cg-RX-API-DMAC7.html)
HK1183436B (en) Intraocular pressure reduction with intracameral bimatoprost implants
HK1183436A (en) Intraocular pressure reduction with intracameral bimatoprost implants
WO2004037246A1 (ja) 神経線維再生促進剤